The mesylate erlotinib salt of imatinib, a tyrosine kinase inhibitor with antineoplastic gefitinib activity. Imatinib binds to an intracellular pocket located armodafinil within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This androgel agent inhibits TK encoded by the bcr-abl oncogene as well as receptor lyrica TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological modafinil malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST). Check for active clinical trials or closed clinical trials using this agent.